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OBJECTIVES: A multi-centre, prospective, observational study aimed to recruit 
500 newly diagnosed AF patients and 500 matched controls to assess AF 
symptom burden and HRQOL using THIN UK primary care data. Patient 
enrolment as soon after diagnosis as possible was vital. Existing methodology of 
identifying patients from fully processed data would not have enrolled patients 
as quickly as necessary to assess newly diagnosed AF. The objective was to 
assess the effectiveness of a novel methodology used to recruit patients as soon 
after diagnosis as possible from THIN. METHODS: Cases and controls matched 
by age, gender and geography were identified as soon as data were received from 
THIN practices rather than after data were fully processed (normal route for 
identifying patients). Patients were therefore identified within one week of 
diagnosis being recorded. Practices were contacted by THIN staff and asked to 
confirm eligibility. Practices invited eligible patients to participate, ensuring no 
direct contact between THIN staff and patients. Patients were asked to complete 
HRQOL questionnaires at enrolment, 6 and 12 months’ follow-up. RESULTS: 
Within 18 months, this method was successful in recruiting beyond the 
necessary sample size (516 case-control pairs). This methodology minimised the 
impact of recruitment and follow-up on clinical management of patients, who 
were seen at a frequency determined in accordance with their normal medical 
care only. Diagnostic assessments of patients were not required and so, other 
than the questionnaires, there was no additional burden to normal clinical 
practice. CONCLUSIONS: This is an innovative method for patient recruitment 
using THIN primary care patient data. Newly diagnosed AF patients who might 
be eligible and for whom clinical information is already available can be quickly 
identified. Large numbers of newly diagnosed patients can be recruited more 
rapidly compared to existing methods and followed up in an efficient and cost-
effective way.  
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OBJECTIVES: To target patients with “personalized” interventions with the 
highest probability of success, understanding what works with other behaviors 
provides empirical guidance, as few outcomes are explicitly medication 
adherence-related. This study's purpose is to glean 1) the characteristics of 
individuals or interventions examined in “tailored” or “targeted” health 
communication interventions, and 2) the components or combination of 
successful strategies tailored to the individual's needs and targeted to the social 
groups in which the patient is embedded. METHODS: A systematic review was 
conducted, with articles identified via searches in MEDLINE and Embase, using 
keywords representing individual, interventional, and behavioral factors. 
Inclusion criteria: published peer-reviewed articles in English, 2000-2012; 77 
studies reflected behavioral outcomes (medication adherence, preventive 
screening, health promotion, and self-management of disease). The review 
specified individual factors (sociodemographic, behavioral, contextual, disease) 
as well as elements upon which interventions were customized (delivery, 
content, form, dose/frequency, setting, level of analysis). RESULTS: Across all 
outcomes assessed (n=133), 52.6% of tailored or targeted interventions 
demonstrated statistically significant benefit, with additional 12.8% effective (not 
statistically), 9.8% mixed, 24.8% non-significant. Regarding behaviors associated 
with multiple morbidities: most studies evidenced health promoting effects 
(medication adherence, 66.7%; diet/obesity, 65.9%; physical activity, 47.4%; 
screening, 71.4%). Disease-specific outcomes reflected stronger findings. 
Individual characteristics were clustered into groups for analysis, with 
significantly positive effects for 3 of 4 clusters: sociodemographic, 59.0%; 
behavioral, 63.4%, contextual, 52.6%. Within group differences indicated support 
for specific factors within each cluster (age vs. education, barriers vs. self-
efficacy). Effects were moderated by intervention-type (tailored vs 
tailored+targeted). CONCLUSIONS: A matrix developed for this review permits a 
refined approach to creating interventions focusing on the interaction (“person x 
intervention”) features of effective strategies. Several candidate characteristics of 
patients to prioritize in medication adherence program development were 
identified, using evidenced-based selection of patient-centered strategies that 
appropriately match what has worked and for whom.  
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OBJECTIVES: We describe the process and progress of the Foundation for the NIH 
Biomarkers Consortium Project Team, a public-private partnership of 
government, academia, non-profit, and industry. The goal is development and 
qualification of a new ABSSSI PRO instrument incorporating reliable, well-
defined and relevant endpoints for patients in terms of how they feel and 
function in clinical trials of antibacterial drugs for ABSSSI. METHODS: We 
adhered to the U.S. Food and Drug Administration (FDA) PRO Guidance for 
instrument development (2009) and the 2010 FDA qualification process for drug 
development tools (DDTs). This guidance describes the process for DDTs 
intended for use in multiple drug development programs, the goal of the current 
effort. Once qualified, drug developers can use DDTs for the qualified context in 
Investigational New Drug (IND) and New Drug Application (NDA)/Biological 
License Application (BLA) submissions without FDA reconsideration of the DDTs 
suitability. RESULTS: The initial phase of instrument development included a 
literature review and gap analysis (see Cimms et al., 2013 ISPOR abstracts) and 
interviews with 9 clinical experts. The most commonly reported symptoms were 
pain and tenderness across all ABSSSI subtypes- cellulitis (n=8), wound infection 
(n=7), and abscess (n=7). These efforts led to the development of a study protocol 
and interview guide to elicit concepts from ABSSSI patients. Following 
qualitative analysis of the interview transcripts, the team will draft a PRO 
instrument based on key concepts identified from ABSSSI patients and experts. 
The draft PRO will be evaluated by an expert panel and refined through cognitive 
debriefing interviews with patients. CONCLUSIONS: A consortium-based 
approach was useful and efficient in developing a new draft PRO measure for 
ABSSSI, which incorporates published literature and data from qualitative 
interviews. The team is planning a similar approach for development of a draft 
clinician reported outcome for ABSSSI and a CABP PRO.  
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OBJECTIVES: a) Determine the effect of utility transformations on the fit of linear 
regression used to map psychometric disease-specific instrument scores to 
disease-specific utility scores and b) determine whether the model fit is 
dependent upon the correlation between the disease specific and non-specific 
items of the preference-based instrument. METHODS: We compare regression 
models mapping scores from the UCLA Prostate Cancer Index (PCI), a 
psychometric instrument measuring Health Related Quality of Life for prostate 
cancer patients, to utility responses from PORPUS-U, a prostate cancer-specific 
utility instrument with disease-specific and generic subscales. Models were 
fitted using a dataset from prostate cancer patients, while fit was assessed on 
three separate datasets, using the Root Mean Squared Error (RMSE) in the 
retransformed scale. The often poor fit of regression-based mapping models may 
be due to limited overlap between the constructs addressed by preference-based 
and psychometric instruments. We investigated this hypothesis employing a 
simulation procedure where we: a) fitted a multivariate regression model 
estimating how the generic subscales depend on the disease-specific ones, b) 
used these estimates, with varying noise, to simulate generic subscale scores, c) 
calculated utility scores from the true disease-specific and simulated generic 
subscales, d) applied linear regression to map PCI scales to “semi”-simulated 
PORPUS-U utilities, and f) evaluated the mapping using RMSE, determining 
whether a “tighter” correlation structure improves the fit. RESULTS: The arcsin 
transformation appears to give the best fit, with RMSE values of 0.0405, 0.0605 
and 0.0457 for the three test datasets. The simulation experiments showed that 
larger correlation between disease specific and non-disease specific instrument 
domains only yields a marginal benefit in the mapping. CONCLUSIONS: 
Transforming utility scores does affect model fit, and appears to be an important 
step in utility mapping. Limited construct overlap between disease-specific and 
generic items in prostate cancer quality of life instruments did not evidently 
explain suboptimal fit in our mapping models.  
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OBJECTIVES: To study to what extent an opt-out option in a Discrete Choice 
Experiment (DCE) influences the attribute estimates and the conclusions drawn 
from the DCE. METHODS: A questionnaire was sent to 2,500 Dutch Diabetes 
Mellitus Type 2 (DM2) patients, each questionnaire contained 9 choice tasks with 
and 9 without an opt-out alternative. Panel-mixed-logit models were used to 
estimate the relative importance of the five attributes included (menu schedule, 
physical activity (PA) schedule, consult structure, expected outcome and out-of-
pocket costs). It was empirically tested whether the relative importance of the 
attributes differed between a DCE with or without opt-out alternative. 
Additionally, it was tested whether results differed between respondents that 
were offered the opt-out option in the first 9 choice tasks and those who could 
choose to opt-out only in the second 9 choice tasks. RESULTS: In both datasets 
(with and without opt-out), consult structure (β=-0.54, β=-0.53), expected 
outcome (β=0.64, β=0.77) and out-of-pocket costs (β=-0.79, β=-0.67) showed 
significant attribute estimates (P<.001). However, the relative importance of 
these attributes differed between both datasets. The frequency of choosing to 
opt-out was higher among participants that first had this option, compared to 
respondents that were first forced to make a choice. The regression analyses on 
these subgroups showed different results with respect to the elaborate PA 
schedule (β=0.10; P>.05 versus β=0.13; P<.05). CONCLUSIONS: Conclusions drawn 
